News & Updates

State-level PBM reform could let employers buy directly from manufacturers. For Miami’s biotech and employer communities, this presents piloting and partnership opportunities—and regulatory and operational risks that must be managed.

To translate discovery into reliable therapies, Miami and South Florida must invest in reproducible infrastructure, transparent data practices, and new funding incentives.

Governor DeSantis’ Floridians First budget commits $4.1B to enhance health across Florida — here’s a focused analysis on regional opportunities, risks, and practical next steps for founders, investors, and institutions.

Machine learning applied to intraoperative laxity measurements offers a path to more objective implant selection, shorter OR workflows, and new opportunities for clinical pilots and medtech partnerships in Miami and South Florida.

The NIH strategic plan reframes disability as a core axis of health equity and research. For Miami and South Florida, this creates near-term opportunity for startups, investors, health systems, and training programs to lead inclusive, scalable solutions.

Federal regulatory shifts at the FDA this year — including frameworks for accelerated pathways and cell/gene therapies — signal evolving expectations for biotech product development.

The initiative is designed to facilitate matchmaking between local talent and companies seeking skilled employees.

The survey aims to identify key challenges and opportunities in South Florida’s biotech ecosystem, helping guide MIA BIO’s strategic efforts.

South Florida’s startup ecosystem raised $754M in Q3 2025, demonstrating growing VC momentum that can be leveraged by biotech investors.

BioStem’s new headquarters in the Research Park at Florida Atlantic University signals operational scaling and local biotech infrastructure growth.